M&A

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

By

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

By

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Tuesday, September 20, 2016

Five things for pharma marketers to know: Tuesday, September 20, 2016

By

GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck

Merkle taps Mike Goldin as SVP of health

Merkle taps Mike Goldin as SVP of health

By

The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.

Five things for pharma marketers to know: Tuesday, September 6, 2016

Five things for pharma marketers to know: Tuesday, September 6, 2016

By

MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug

In Medivation deal, Pfizer will gain an oncology blockbuster

In Medivation deal, Pfizer will gain an oncology blockbuster

By

Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.

Expect healthcare agencies to make more digital acquisitions: report

Expect healthcare agencies to make more digital acquisitions: report

By

Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

By

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

By

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

Five things for pharma marketers to know: Monday, April 4, 2016

Five things for pharma marketers to know: Monday, April 4, 2016

By

Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

By

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Precision for Medicine receives $75 million investment

By

Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.

Pfizer and Allergan merger to create uncertainty for agencies, execs say

Pfizer and Allergan merger to create uncertainty for agencies, execs say

By

The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.

Accenture acquires Swiss pharma agency, adds digital marketing expertise

Accenture acquires Swiss pharma agency, adds digital marketing expertise

By

The consultancy purchased Boomerang Pharmaceutical Communications, its sixth acquisition in the past 12 months.

Five things for pharma marketers to know: Friday, December 4, 2015

Five things for pharma marketers to know: Friday, December 4, 2015

By

Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease

Pfizer, Allergan to merge, creating pharma giant

Pfizer, Allergan to merge, creating pharma giant

By

The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.

Five things for pharma marketers to know: Monday, November 23, 2015

Five things for pharma marketers to know: Monday, November 23, 2015

By

Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor

Five things for pharma marketers to know: Friday, November 20

Five things for pharma marketers to know: Friday, November 20

By

AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal

Five things for pharma marketers to know: Thursday, November 19, 2015

Five things for pharma marketers to know: Thursday, November 19, 2015

By

Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups

Five things for pharma marketers to know: Monday, November 2, 2015

Five things for pharma marketers to know: Monday, November 2, 2015

By

Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn't plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign

Five things for pharma marketers to know: Thursday, October 29, 2015

Five things for pharma marketers to know: Thursday, October 29, 2015

By

Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren't worth the money; pharmacy tied to Valeant used "back-door" sales tactics

Five things for pharma marketers to know: Wednesday, October 28, 2015

Five things for pharma marketers to know: Wednesday, October 28, 2015

By

Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy

Five things for pharma marketers to know: Wednesday, October 14, 2015

Five things for pharma marketers to know: Wednesday, October 14, 2015

By

J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies

Five things for pharma marketers to know: Wednesday, September 16, 2015

Five things for pharma marketers to know: Wednesday, September 16, 2015

By

Obama nominates Robert Califf as FDA commissioner; The Huffington Post debuts investigative series on J&J; Amgen acquires cholesterol-lowering drug

Five things for pharma marketers to know: Tuesday, September 8, 2015

Five things for pharma marketers to know: Tuesday, September 8, 2015

By

Roche CEO sounds off on UK health system cost controls; Concordia Healthcare buys rare-disease drugmaker; Cipla acquires two generic drugmakers

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

By

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Inovalon scoops up consultancy Avalere Health

Inovalon scoops up consultancy Avalere Health

By

The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

By

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

OPINION

Email Newsletters